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Summary 
Galectins are a group of animal lectins characterized by their specificity for β-galactosides. Mouse 
galectin-2 (mGal-2) is predominantly expressed in the gastrointestinal tract and has been identified as 
one of the main gastric mucosal proteins that are uniquely sensitive to S-nitrosylation. We have 
previously reported that oxidation of mGal-2 by hydrogen peroxide (H2O2) resulted in the loss of 
sugar-binding ability, whereas pretreatment of mGal-2 with S-nitrosocysteine prevented H2O2-
induced inactivation. In this study, we used point-mutated recombinant mGal-2 proteins to study 
which of the two highly conserved Cys residues in mGal-2 must be S-nitrosylated for protection 
against oxidative inactivation. Mutation of Cys57 to a Met residue (C57M) did not result in lectin 
inactivation following H2O2 treatment, whereas Cys75 mutation to Ser (C75S) led to significantly 
reduced lectin activity, as is the case for wild-type mGal-2. However, pretreatment of the C75S 
mutant with S-nitrosocysteine protected the protein from H2O2-induced inactivation. Therefore, Cys57 
is suggested to be responsible for oxidative inactivation of the mGal-2 protein, and protection of the 
sulfhydryl group of the Cys57 in mGal-2 by S-nitrosylation is likely important for maintaining mGal-2 
protein function in an oxidative environment such as the gastrointestinal tract.  
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Introduction 
Galectins comprise a group of animal lectins that specifically bind to β-galactosides and are 
characterized by an evolutionarily conserved amino acid sequence motif in the carbohydrate-binding 
site (1–3). Galectins are known to be involved in a wide variety of biological processes including 
development, cell differentiation, tumor metastasis, apoptosis, RNA splicing, and immune regulation 
(4, 5). 
Among the galectins, galectin-2 (Gal-2) was first identified to be highly expressed in gastric cells, 
predominantly in epithelial cells of the rat stomach (6). Gastric mucous cells exhibit strong Gal-2 
immunoreactivity, with expression observed in the small intestine (7); GAL2 mRNA has also been 
detected in the human stomach (8). Taken together, the expression of Gal-2 in the gastrointestinal 
tract and the amelioration of acute and chronic colitis in mice by Gal-2 overexpression (9) as well as 
the reduced expression of human Gal-2 associated with lymph node metastasis in gastric cancer (10) 
and in Helicobacter-induced gastric cancer progression (11) have suggested that Gal-2 exerts a 
protective function in the gastrointestinal tract. 
Gal-2 was identified in a screen of mouse gastric mucosal proteins that are uniquely sensitive to S-
nitrosylation (12). This process, which involves the coupling of an NO group to the reactive thiol of a 
cysteine (Cys) residue in a polypeptide, is known to be an important post-translational modification in 
a variety of proteins (13). In addition to the NO generated enzymatically by NO synthase (NOS) from 
L-arginine by various cells including neurons and vascular endothelial cells, in which it functions as a 
signaling molecule, large quantities of NO are known to be generated in the stomach by non-
enzymatic acid reduction of salivary nitrite to exert various physiological functions in the 
gastrointestinal tract (14–17) including as a barrier in the stomach (18–20). Several studies, including 
a study demonstrating that nitrate administration ameliorates dextran sulfate sodium-induced acute 
experimental colitis in mice (21), have suggested that the NO generated in the gastrointestinal tract 
might also have a protective role therein. 
In contrast, reactive oxygen species (ROS) such as hydrogen peroxide (H2O2) can cause oxidative 
stress that could result in variety of disorders in the gastrointestinal tract including ulcers, 
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inflammatory bowel disease, and gastric and colorectal cancer (22). In our previous report (23), we 
found that although oxidation of mouse galectin-2 (mGal-2) by H2O2 resulted in the loss of sugar-
binding activity, mGal-2 pretreatment with S-nitrosocysteine (CysNO) to effect S-nitrosylation 
prevented the H2O2-induced inactivation, presumably by protecting the Cys residues (Cys57 and Cys75) 
in the protein that are highly conserved across mammals (24). Furthermore, analysis of mGal-2 
proteins with site-directed mutations at the Cys57 and /or Cys75 positions suggested that both Cys 
residues were fully S-nitrosylated (23). In this report, we utilized wild-type and mutant forms of 
mGal-2 to investigate which of the two Cys residues in mGal-2 is responsible for its inactivation by 
H2O2-induced oxidation. 
 
Materials and Methods 
 
Expression and purification of recombinant mGal-2 
The expression and purification of recombinant wild-type Gal-2 and the three mutated forms of mGal-
2, C57M (Cys57 mutated to Met), C75S (Cys75 mutated to Ser), and C57M/C75S (Cys57 and Cys75 
mutated to Met and Ser, respectively), were performed as previously described (23). 
 
Measurement of protein concentration 
Protein concentration was determined by Bradford’s method (25) using bovine serum albumin as a 
standard. 
 
Pretreatment reaction of recombinant mGal-2 proteins with CysNO for S-nitrosylation 
The S-nitrosylation of the wild type and mutated forms of mGal-2 protein was performed as 
previously described (23). To remove unreacted CysNO, samples were ultrafiltered using Amicon 
Ultra centrifuge tubes (Millipore, Billerica, MA, USA). 
 
Saville-Griess assay 
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The number of S-nitrosylated molecules was measured using the Saville-Griess assay as previously 
described (23, 26). 
 
Oxidation of mGal-2 by H2O2 
The H2O2 concentration was measured at 240 nm (ε240 = 43.6 L/mol·cm). S-nitrosylated mGal-2 was 
incubated with 10 mM H2O2 for 2 h in the dark (23).  
 
Binding of Gal-2 recombinant proteins to lactose after treatment with H2O2 
C57M and C75S were treated with H2O2 and then subjected to a lactose-immobilized agarose (J-Oil 
Mills, Inc., Tokyo, Japan) column (bed volume 1 ml) as previously described (23). C75S was also 
pretreated with CysNO, followed by reaction with H2O2, and subjected to a lactose-immobilized 
agarose column as well. 
  
Hemagglutination assay 
The hemagglutination activity of the recombinant mGal-2 proteins was measured as previously 
reported (23, 27). Briefly, a 25-μl sample of mGal-2 treated with CysNO and/or H2O2 was serially 
diluted 2-fold in a 96-well V-shaped microtiter plate, followed by the addition of 50 μl of EDTA-PBS 
and 25 μl of 4% (v/v) glutaraldehyde-fixed rabbit erythrocytes in EDTA-PBS. After the samples were 
allowed to stand for 1 h at room temperature, the end-point showing the minimum concentration 
resulting in hemagglutination was determined. 
 
Circular dichroism (CD) spectra of recombinant mGal-2 mutants 
The CD spectra of recombinant proteins at the concentration of 0.25 mg/ml in EDTA-PBS with or 
without 10 mM H2O2 were obtained using a J-720WI spectropolarimeter (JASCO Corporation, Tokyo, 
Japan). 
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SDS-PAGE under non-reducing and reducing conditions 
The recombinant wild-type mGal-2 protein and its mutant forms, C57M, C75S, or C57M/C75S, were 
treated with or without H2O2 for 2 h in EDTA-PBS buffer. After the addition of catalase to quench the 
activity of the H2O2, sample buffer for SDS-PAGE with or without β-mercaptoethanol was added to 
the reaction mixture and the samples were incubated for 10 min at 70°C and subsequently subjected to 
SDS-PAGE. The gels were stained with Coomassie brilliant blue. 
 
Crosslinking reaction using bis(sulfosuccinimidyl)suberate (BS3) 
The crosslinking reaction to detect multimer formation of the recombinant galectins using the BS3 
crosslinking reagent (Thermo Fisher Scientific Inc., Waltham, MA, USA) was performed as 
previously described (23), with some modifications. Briefly, after the S-nitrosylation reaction, 
recombinant mGal-2 (5 µg in 50 µL) was incubated with 0.3 mM BS3 for 30 min in EDTA-PBS at 
room temperature. Samples were resolved by SDS-PAGE, and the gel was stained with Oriole stain 
(Bio-Rad). 
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Results 
Binding capacity of recombinant mGal-2 to lactose 
Recombinant wild-type mGal-2 was adsorbed to a lactose-immobilized agarose column and eluted 
with 0.1 M lactose. Oxidation of mGal-2 by H2O2 resulted in the loss of this binding ability and the 
recombinant mGal-2 ended up in the flow-through fraction, whereas pretreatment of mGal-2 with 
CysNO prior to the reaction with H2O2 prevented this binding inactivation and resulted in the 
generation of a lactose-eluted fraction (23). In this report, we used site-directed mutants of mGal-2, 
C57M, and C75S, and determined their susceptibility to H2O2-induced oxidation. To obtain the 
recombinant protein of the two mutants, C57M and C75S, recombinant proteins were expressed in E. 
coli and were subjected to a asialofetuin-immobilized agarose column with elution in 0.1 M lactose 
(data not shown) as described previously (23).  
When recombinant C57M and C75S mGal-2 proteins were subjected to the lactose-immobilized 
agarose column after H2O2 treatment, only the C57M mGal-2 protein was adsorbed to the column and 
eluted with lactose (Fig. 1A). In contrast, as was the case for the wild-type mGal-2, the C75S mutant 
seemed to lose substantial ability to interact with immobilized lactose upon H2O2 treatment, and a 
large amount of the recombinant protein was observed in the flow-through fraction (Fig. 1B). 
However, when this C75S protein was pretreated with CysNO prior to the reaction with H2O2, the 
effect of H2O2 treatment disappeared, and the protein was adsorbed to the column and eluted with 
lactose (Fig. 1C); this outcome was the same as that observed for the wild-type mGal-2 treated with 
CysNO (23).  
 
Hemagglutination activity 
Similar to the results of the binding assay, the C57M mutant form of mGal-2 retained its 
hemagglutination activity after treatment with H2O2, whereas the wild-type form of mGal-2 lost this 
activity subsequent to H2O2-treatment (Fig. 2 line A (untreated) and 2B (H2O2-treated) wild-type 
mGal-2; Fig. 2D (untreated) and 2E (H2O2-treated) C57M). In contrast, treatment of the C75S mutant 
with H2O2 resulted in a 4-fold loss of hemagglutination activity (Fig. 2G, (untreated) and 2H (H2O2 
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treated) C75S). However, when C75S was incubated with CysNO prior to H2O2 treatment, the C75S 
mutant retained its hemagglutination activity (Fig. 2I), which was the same as the outcome for the 
wild-type protein (Fig. 2 C). For the Cys-less mutant C57M/C75S, the results were similar to those of 
the C57M mutant (Fig. 2J-L), in that no reduction in hemagglutination activity was observed even 
after H2O2 treatment. 
 
CD spectrometry analysis of recombinant protein secondary structure 
The CD spectra of the recombinant proteins dissolved in EDTA-PBS are shown in Fig. 3. Wild-type 
mGal-2 showed a typical β-sheet structure profile having a negative peak at the wavelength of 215 nm 
(Fig. 3A, thick bold line) resembling that of human galectin-1 (28); this peak was lost in the spectrum 
of H2O2-treated mGal-2 (Fig. 3A, thin line). When wild-type mGal-2 was incubated with CysNO prior 
to H2O2 treatment, the CD spectrum remained the same even after H2O2 treatment (Fig. 3A, dotted 
line). For C57M and the Cys-less form of mGal-2, in which Cys57 is mutated to a Met residue, the CD 
spectrum remained the same even after H2O2 treatment or incubation with CysNO (Fig. 3B (C57M), 
3D (C57M/C75S)). However, when the C75S mutant, which retained the Cys57 residue in its 
polypeptide chain, was treated with H2O2, the change in the CD spectrum was the same as that 
observed for wild-type mGal-2; i.e., the typical peak resulting from the rich β-sheet structure was lost 
after H2O2 treatment but was retained when the C75S mutant was pretreated with CysNO prior to 
H2O2 treatment (Fig. 3C). 
 
SDS-PAGE under reducing conditions 
To test the formation of disulfide bonds between the Cys residues in the same polypeptide chain 
and/or two different polypeptide chains, recombinant proteins were treated with H2O2 and subjected to 
SDS-PAGE under reducing or non-reducing conditions; i.e., with or without β-mercaptoethanol in the 
sample buffer, respectively. Wild-type mGal-2 and the C57M, C75S, and C57M/C75S (Cys-less) 
forms of mGal-2 migrated to the position of a monomer at approximately 15 kDa under non-reducing 
conditions (Fig. 4A, lanes 1, 3, 5, and 7), and this result did not change after H2O2 treatment (Fig. 4A, 
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lanes 2, 4, 6, and 8). Similar results were obtained when the samples were treated with β-
mercaptoethanol prior to SDS-PAGE (Fig. 4B), suggesting that no disulfide formation occurred after 
H2O2 treatment. 
 
Detection of multimer formation of the wild-type and Cys-mutated mGal-2 proteins after H2O2 
treatment by addition of the crosslinker BS3 
To test the change in multimerization of the recombinant proteins generated by H2O2 treatment, the 
recombinant proteins were incubated with the crosslinker BS3 after H2O2 treatment, followed by SDS-
PAGE and Oriole staining. When wild-type mGal-2 was incubated with BS3, two primary bands were 
detected (Fig. 5, lane 1; the bands are indicated by single or double arrowheads). An additional band 
with a higher molecular weight was also observed after mGal-2 treatment with H2O2 (Fig. 5, lane 2; 
triple arrowheads). This additional band was not observed when the wild-type mGal-2 was pretreated 
with CysNO prior to H2O2 addition (Fig. 5, lane 3). The results for the C75S mutant, which still 
retains the intact Cys57, were similar to those of the wild-type protein regarding the appearance of the 
higher-molecular-weight band (Fig. 5, lanes 7–9). However, when the two mutant proteins C57M and 
C57M/C75S, in which the Cys57 residue has been mutated to Met, were examined, the higher-
molecular-weight bands were not observed after H2O2 treatment (Fig. 5, lanes 4–6 and 10–12). 
 
Discussion 
The polypeptide chain of mGal-2 contains two Cys residues within 130 amino acids; these two 
Cys residues are highly conserved among mammalian galectin-2 proteins. We have previously shown 
that mGal-2 loses its sugar-binding and hemagglutination ability by oxidative inactivation after 
treatment with H2O2 and that this inactivation can be prevented by pretreatment with CysNO (23). 
Furthermore, by using recombinant site-directed mutant proteins of mGal-2, i.e., C57M, C75S, and 
C57M/C75S, our results suggest that the two Cys residues, Cys57 and Cys75, are both S-nitrosylated by 
treatment with CysNO (23).  
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The Cys57 residue was changed to Met instead of Ser because the C57S mutant had low solubility 
as previously reported (23, 29). Because the two mutants, C57M and C75S, were both adsorbed onto 
the asialofetuin-agarose column and could be eluted specifically with 0.1 M lactose, with an elution 
profile similar to that of wild-type mGal-2 (data not shown), the amino acid substitutions did not 
affect the binding activity of the two mutants for β-galactoside-containing sugar structures. We also 
tried to express the recombinant C57A protein of mGal-2 (Cys57 residue changed to Ala) to eliminate 
any potential effects of the modification of the Met residue. However, this mutant also had low 
solubility and it was difficult to obtain sufficient amounts of the recombinant protein, as previously 
reported (23, 29). 
When the ability of the recombinant proteins to be adsorbed to β-galactosides was tested after 
H2O2-treatment, the C57M mutant retained its ability to bind to the β-galactoside-immobilized 
column and was eluted specifically with lactose. In contrast, for the C75S mutant treated with H2O2, a 
substantial amount of the protein was found in the flow-through fraction, indicating that oxidative 
inactivation caused the loss of the sugar-binding ability of the protein. The finding that some 
remaining proteins were still adsorbed to the column likely resulted from the residual recombinant 
proteins not being fully inactivated because of the high concentration of the recombinant protein in 
the solution. However, when the C75S mutant was pretreated with CysNO prior to exposure of the 
protein to H2O2, the loss of the sugar-binding ability was abrogated, similar to the outcome observed 
for the wild-type protein as reported in our previous study (23). Furthermore, when the 
hemagglutination activities of these mutants were tested, the C75S mutant showed a substantial loss 
of hemagglutination following exposure to H2O2, whereas pretreatment with CysNO abrogated this 
loss of function, again as observed for wild-type mGal-2. In contrast, neither the sugar-binding nor the 
hemagglutination ability of C57M or C57M/C75S was reduced by H2O2 treatment. Because the wild-
type and C75S mutant, which retained an intact Cys57 residue, were susceptible to H2O2-induced 
oxidative inactivation, whereas the C57M and C57M/C75S mutants, which did not have the –SH 
group of the Cys57 residue, were not, these results suggest that the Cys57 residue in the mGal-2 protein 
is responsible for the H2O2-induced oxidative inactivation of mGal-2. Furthermore, protecting this 
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Cys57 by CysNO treatment appears to be critical for protecting the lectin ability of mGal-2 from 
oxidative inactivation. 
Galectins, including Gal-2, have a typical structure that is rich in β-strands (30) and have a 
typical β-sheet profile, with a negative peak on CD analysis at 215 nm as shown in Fig 3A for wild-
type mGal-2 (solid line). When the lectin is treated with H2O2, this typical negative peak disappears, 
indicating that the secondary structure of the lectin has been lost. However, mutants C57M and 
C57M/C75S, whose Cys57 is mutated to Met and which do not have the –SH at this position, 
maintained their basic spectra even after H2O2 treatment. Furthermore, when the wild-type protein and 
C75S mutant, which retained the –SH side chain at the Cys57 position, were pretreated with CysNO 
prior to H2O2 exposure, they maintained their CD spectrum with the typical negative peak for the β-
strands even after H2O2 treatment. These results suggest that the secondary structure remained intact, 
possibly as a result of S-nitrosylation of the Cys57 residue. Therefore, we concluded that the oxidation 
of the Cys57 residue by H2O2 treatment induces degeneration of the lectin structure and results in loss 
of lectin activities such as β-galactoside binding and erythrocyte hemagglutination, and that protection 
of the –SH group on the Cys57 residue by CysNO pretreatment retains their activity under oxidative 
inactivating conditions. 
The SDS-PAGE result shown in Fig. 4 indicates that H2O2 treatment does not induce the 
formation of disulfide bridges between the two mGal-2 molecules. A very faint band that corresponds 
to the position of a possible dimer was observed in the case of the C75S mutant after H2O2-treatment; 
this band probably resulted from the boiling in the sample buffer without β-ME prior to SDS-PAGE. 
Furthermore, from the result of the cross-linking experiment, the denaturation of the mGal-2 protein 
by H2O2 treatment might have exposed the hydrophobic region originally folded inside the structure, 
thus resulting in a multimeric aggregation product. In fact, after treatment with H2O2, an insoluble 
precipitant was observed in the tube (not shown).  
According to the X-ray crystallographic structure of human Gal-2 in complex with lactose (30), 
the Cys75 residue exists on the other side of the mGal-2 molecule from the surface involved in dimer 
formation. Therefore, it is highly unlikely that the two Cys75 residues in the mGal-2 homodimer form 
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a disulfide bond in an oxidative environment. However, very small amount of artificial dimer 
generated by the disulfide bond formation between the two Cys75 residues from two independent 
mGal-2 molecules, resulting in another very faint band for the H2O2-treated C57M mutant of mGal-2 
(Fig. 4A, lane 4), may underlie the stronger hemagglutination activity observed for the wild-type 
protein and C57M mutant treated with H2O2 (Fig. 4, lines C, E, and F. For line B, the wild-type mGal-
2 is inactivated by oxidation via Cys57.) The C57M/C75S mutant, which does not have Cys75, did not 
show this stronger hemagglutination activity after H2O2 treatment (Fig. 4, lines K and L), which could 
support this idea. 
Gal-1 is known to form intramolecular disulfide bonds (31) and to have different biological 
functions depending on its redox status (28, 32–35). However, Gal-1 has also been shown to be 
inactivated by oxidation using H2O2, and redox regulation has been reported to be involved in the 
structure-function relationship of Gal-1 (28). Furthermore, oxidation of the chicken galectin CG-1B 
(C14) leads to two forms of homodimers through formation of either an intrasubunit disulfide bond 
between Cys2 and Cys7 or an intersubunit disulfide bond between the two Cys7 (36). Thus, the 
function of Gal-2 in the stomach might also be regulated by its redox status, and S-nitrosylation could 
play an important role in this regulation. However, although the loss of lectin activity of Gal-1 is 
reported to result from formation of intramolecular disulfide bonds, this cannot be the case for the 
oxidative inactivation of mGal-2 because the C75S mutant, which only has one Cys residue remaining 
at the Cys57 position, is also susceptible to inactivation by H2O2 treatment. 
Protein tyrosine phosphatases (PTPs) are reported to be reversibly oxidized and inactivated when 
cells are treated with H2O2, and they are thus suggested to be regulated by oxidization (37). PTP1B, 
an enzyme of the PTP family that is important for negative regulation of the insulin receptor (38,39), 
is oxidized by H2O2 at the essential residue Cys215 (40). This Cys215 residue has been proposed to be 
reversibly inactivated to sulfenic acid (40), and it has also been reported that this Cys residue could be 
irreversibly oxidized to sulfinic or sulfonic acid states (41) and that S-nitrosylation of Cys215 protected 
PTP1B from oxidation-induced inactivation (42). X-ray crystallographic analysis of PTP1B showed 
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that, during reversible inactivation, Cys215 was oxidized to sulfenic acid and then to a sulphenyl-amide 
structure, which forced a conformational change in the main chain of the protein (43,44).  
Cys57 is located in the middle of the carbohydrate-binding cassette with its side chain sulfhydryl 
group protruding to the side opposite that of the β-sheet that binds lactose. A conformational change 
similar to that in PTP1B (43, 44) induced by oxidation of the Cys57 residue in mGal-2 could be the 
cause of the loss of the binding ability of mGal-2 for the β-galactoside-containing column and also the 
loss of the hemagglutination activity of this protein. However, considering that the typical peak 
resulting from the rich β-sheet structure was lost in the CD spectra of both the wild-type and C75S 
proteins when treated with H2O2, and that a higher-molecular-weight complex was formed as shown 
in Fig. 5, some portion of this protein could be irreversibly oxidized to the sulfinic or sulfonic acid 
states at the Cys57 residue, resulting in permanent degeneration of the whole structure. Although it 
remains unclear whether the oxidation at this position is reversible at the sulfenic acid level or 
irreversible at the sulfinic or sulfonic acid level, protection of the sulfhydryl group of Cys57 by S-
nitrosylation should be beneficial for maintaining lectin activity under oxidative stress, as there were 
no substantial differences in the sugar-binding profile or hemagglutination activity of mGal-2 with 
and without CysNO treatment (23). 
It has been reported that Gal-1 is also S-nitrosylated at Cys43 and Cys61 (45); notably, Cys61 is 
located at the position corresponding to Cys57 of Gal-2. Additional experiments to determine whether 
or not Gal-1 is also protected from oxidative inactivation by S-nitrosylation are therefore warranted.  
In conclusion, our study demonstrated that Cys57 is likely to be responsible for oxidative 
inactivation of the mGal-2 protein and that protection of the sulfhydryl group of the Cys57 in mGal-2 
by S-nitrosylation might be important for maintaining mGal-2 protein function in an oxidative 
environment such as the gastrointestinal tract. The strong immunoreactivity observed in gastric 
mucous cells and the suggestion that Gal-2 might have a protective function in the gastrointestinal 
tract indicates that Gal-2 might have a role similar to that of Gal-3, which has been reported to play an 
important role in maintaining mucosal barrier function through carbohydrate-dependent interactions 
with cell surface mucins (46, 47). Furthermore, because the NO generated in the gastrointestinal tract 
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has been suggested to have a protective role therein, and no substantial changes in the carbohydrate 
binding activity have been detected between the S-nitrosylated and non-S-nitrosylated forms of Gal-2, 
it is conceivable that the S-nitrosylation of Cys57 in Gal-2 might be one of the main factors 
maintaining the interactions of Gal-2 with carbohydrate-containing molecules in the stomach mucus 
such as mucins, resulting in a more stable mucosal barrier function. To build on these results, more 
detailed analyses of the molecular mechanisms underlying oxidative inactivation and the means by 
which this inactivation is prevented by CysNO pretreatment are necessary and ongoing in our 
laboratory. 
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Figure legends 
 
Fig. 1 Effect of H2O2 treatment on the sugar-binding profiles of recombinant mGal-2 C57M, 
C75S, and C75S pretreated with CysNO.  
 20 
Purified recombinant mGal-2 mutants (C57M and C75S) were treated with 10 mM H2O2 for 2 h in the 
dark, added to a lactose-immobilized agarose column, washed with EDTA-PBS, and eluted with 
lactose. The elution profiles of mGal-2 were verified by measuring the protein concentration of each 
fraction (0.5 ml each) in addition to SDS-PAGE analysis. Bands at approximately 15 kDa, the 
molecular weight of the mGal-2 monomer, were detected by Coomassie brilliant blue staining. 
Profiles of recombinant mGal-2 C57M (A), C75S (B), and mGal-2 C75S pretreated with CysNO 
(CysNO+) before H2O2 treatment (C) as eluted from the lactose-immobilized agarose. 
 
Fig. 2 Effect of H2O2 treatment on the hemagglutination of mGal-2 mutants pretreated with 
CysNO.  
mGal-2 mutants were treated with 10 mM H2O2 for 2 h in the dark and the treated recombinant 
protein (250 µg/mL) was diluted 2-fold in a 96-well microtiter plate. A suspension of glutaraldehyde-
fixed rabbit erythrocytes in EDTA-PBS was added and the hemagglutination activity was determined 
after a 1 h of incubation. Lanes A, B, and C, wild-type mGal-2; lanes D, E, and F, C57M mutant; 
lanes G, H, and I, C75S mutant; lanes J, K, and L, C57M/C75S mutant. 
 
Fig. 3 Effect of H2O2 treatment on the secondary structure of mGal-2 mutants pretreated with 
CysNO. 
The CD spectra of recombinant mGal-2 mutants, recombinant proteins treated with 10 mM H2O2 for 2 
h in the dark, and recombinant proteins pretreated with CysNO and treated with H2O2 are shown for 
(A) wild-type, (B) C57M, (C) C75S, and (D) C57M/C75S.  
 
Fig. 4 SDS-PAGE analysis of H2O2-treated mGal-2 mutants under non-reducing and reducing 
conditions. 
Recombinant mGal-2 was treated with 10 mM H2O2 for 2 h in the dark and was subjected to SDS-
PAGE under non-reducing (A) and reducing (B) conditions. 
 
 21 
Fig. 5 Detection of multimer formation of H2O2-treated mGal-2 using the crosslinker BS3.  
BS3 was added to a recombinant mGal-2 solution with (CysNO+) or without (CysNO−) pretreatment 
prior to addition of H2O2 (H2O2+). The reaction mixture was subjected to SDS-PAGE and the gel was 
stained with Oriole. The results for wild-type and C57M mutant proteins are shown in (A), and those 
for the C75S and C57M/C75S mutants are shown in (B). The positions of the Gal-2 monomer, dimer, 
and multimer are shown by one, two, or three arrowheads, respectively. The bands for catalase, which 
is added to remove the remaining H2O2 activity, are also indicated. 
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